NCT03618056View on ClinicalTrials.gov

Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

July 17, 2020

Study Completion Date

July 17, 2020

Conditions
HIV InfectionsSystemic Lupus Erythematosus
Interventions
BIOLOGICAL

AIDSVAX® B/E

Administered by intramuscular injection

Trial Locations (1)

27710

Duke Human Vaccine Institute CRS, Durham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03618056 - Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter